Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with...

by Joseph P Eder, Sarina A Piha-Paul, Claude Gimmi, Vera Hildebrand, Vinayak Hosagrahara, Christina Habermehl
Published 2020-07-01

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

by Jeffrey A. How, Amir A. Jazaeri, Pamela T. Soliman, Nicole D. Fleming, Jing Gong, Sarina A. Piha-Paul, Filip Janku, Bettzy Stephen, Aung Naing
Published 2021-02-01

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

by Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock, Gerald Falchook
Published 2020-04-01

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.

by Denis L Jardim, Jennifer J Wheler, Kenneth Hess, Apostolia M Tsimberidou, Ralph Zinner, Filip Janku, Vivek Subbiah, Aung Naing, Sarina A Piha-Paul, Shannon N Westin, Sinchita Roy-Chowdhuri, Funda Meric-Bernstam, David S Hong
Published 2014-01-01

Associations between the gut microbiome and fatigue in cancer patients

by Joud Hajjar, Tito Mendoza, Liangliang Zhang, Siqing Fu, Sarina A. Piha-Paul, David S. Hong, Filip Janku, Daniel D. Karp, Alexej Ballhausen, Jing Gong, Abdulrazzak Zarifa, Christine B. Peterson, Funda Meric-Bernstam, Robert Jenq, Aung Naing
Published 2021-03-01

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

by Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Published 2019-03-01

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

by Mehmet Altan, Lilibeth Castillo, Bettzy Stephen, Sarina A Piha-Paul, Tito Mendoza, Goldy George, Enedelia Rodriguez, Christine Peterson, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Abdulrazzak Zarifa, Lacey M McQuinn, Charles Cleeland
Published 2020-07-01

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

by Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock
Published 2014-01-01

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

by Bert H O'Neil, John M Wallmark, David Lorente, Elena Elez, Judith Raimbourg, Carlos Gomez-Roca, Samuel Ejadi, Sarina A Piha-Paul, Mark N Stein, Albiruni R Abdul Razak, Katia Dotti, Armando Santoro, Roger B Cohen, Marlena Gould, Sanatan Saraf, Karen Stein, Sae-Won Han
Published 2017-01-01

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

by Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Published 2019-07-01